Joshua D. Grill, Margaret D. Mastrolorenzo, Heather M. Snyder, Maria C. Carrillo, Ronald C. Petersen, Paul Aisen, Reisa Sperling, Kedir Hussen, Rema Raman
{"title":"5年ADRD临床试验推进方法与方案研究所（IMPACT-AD）","authors":"Joshua D. Grill, Margaret D. Mastrolorenzo, Heather M. Snyder, Maria C. Carrillo, Ronald C. Petersen, Paul Aisen, Reisa Sperling, Kedir Hussen, Rema Raman","doi":"10.1002/alz.70441","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> BACKGROUND</h3>\n \n <p>First held in 2020, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a program to train the next generation of Alzheimer's disease (AD) and related dementias (AD/ADRD) clinical trialists.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>IMPACT-AD includes didactic, workshop, and small group components.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>IMPACT-AD has trained 18 alumni–scholars (accepted from 424 applicants), of whom 67% were female. Forty-eight (26%) were the first in their family to attend college. Scholars included individuals from all racial and ethnic groups. Each year, participants demonstrated increased learning about AD/ADRD clinical trials through a pre/post-test model of knowledge assessments. Among those completing annual follow-up surveys, >84% remain in AD/ADRD trials careers, and 80% have experienced career advances or milestones. In the latter group, > 90% indicated that participating in IMPACT-AD contributed to this career growth.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>IMPACT-AD is a novel educational program that is achieving its goals.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Over 5 years, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) has trained 188 scholars.</li>\n \n <li>The course has been accessible to a broad range of trainees who were diverse in professional and demographic backgrounds.</li>\n \n <li>Objective assessments indicate that participants gain knowledge through participation.</li>\n \n <li>Eighty-four percent of trainees have remained in Alzheimer's disease and related dementias (ADRD) trials careers.</li>\n \n <li>Eighty percent of alumni have experienced career advances; nearly all indicated that participating in the course contributed to their success.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 7","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70441","citationCount":"0","resultStr":"{\"title\":\"Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD)\",\"authors\":\"Joshua D. Grill, Margaret D. Mastrolorenzo, Heather M. Snyder, Maria C. Carrillo, Ronald C. Petersen, Paul Aisen, Reisa Sperling, Kedir Hussen, Rema Raman\",\"doi\":\"10.1002/alz.70441\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> BACKGROUND</h3>\\n \\n <p>First held in 2020, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a program to train the next generation of Alzheimer's disease (AD) and related dementias (AD/ADRD) clinical trialists.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>IMPACT-AD includes didactic, workshop, and small group components.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>IMPACT-AD has trained 18 alumni–scholars (accepted from 424 applicants), of whom 67% were female. Forty-eight (26%) were the first in their family to attend college. Scholars included individuals from all racial and ethnic groups. Each year, participants demonstrated increased learning about AD/ADRD clinical trials through a pre/post-test model of knowledge assessments. Among those completing annual follow-up surveys, >84% remain in AD/ADRD trials careers, and 80% have experienced career advances or milestones. In the latter group, > 90% indicated that participating in IMPACT-AD contributed to this career growth.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>IMPACT-AD is a novel educational program that is achieving its goals.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Over 5 years, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) has trained 188 scholars.</li>\\n \\n <li>The course has been accessible to a broad range of trainees who were diverse in professional and demographic backgrounds.</li>\\n \\n <li>Objective assessments indicate that participants gain knowledge through participation.</li>\\n \\n <li>Eighty-four percent of trainees have remained in Alzheimer's disease and related dementias (ADRD) trials careers.</li>\\n \\n <li>Eighty percent of alumni have experienced career advances; nearly all indicated that participating in the course contributed to their success.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":7471,\"journal\":{\"name\":\"Alzheimer's & Dementia\",\"volume\":\"21 7\",\"pages\":\"\"},\"PeriodicalIF\":13.0000,\"publicationDate\":\"2025-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70441\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer's & Dementia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/alz.70441\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/alz.70441","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD)
BACKGROUND
First held in 2020, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) is a program to train the next generation of Alzheimer's disease (AD) and related dementias (AD/ADRD) clinical trialists.
METHODS
IMPACT-AD includes didactic, workshop, and small group components.
RESULTS
IMPACT-AD has trained 18 alumni–scholars (accepted from 424 applicants), of whom 67% were female. Forty-eight (26%) were the first in their family to attend college. Scholars included individuals from all racial and ethnic groups. Each year, participants demonstrated increased learning about AD/ADRD clinical trials through a pre/post-test model of knowledge assessments. Among those completing annual follow-up surveys, >84% remain in AD/ADRD trials careers, and 80% have experienced career advances or milestones. In the latter group, > 90% indicated that participating in IMPACT-AD contributed to this career growth.
DISCUSSION
IMPACT-AD is a novel educational program that is achieving its goals.
Highlights
Over 5 years, the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) has trained 188 scholars.
The course has been accessible to a broad range of trainees who were diverse in professional and demographic backgrounds.
Objective assessments indicate that participants gain knowledge through participation.
Eighty-four percent of trainees have remained in Alzheimer's disease and related dementias (ADRD) trials careers.
Eighty percent of alumni have experienced career advances; nearly all indicated that participating in the course contributed to their success.
期刊介绍：
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
